Saturday 17 October 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
22.04
0.66
−2.91%
Follow TNGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
14.02 | 16.50 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(30.11) | (34.63) | — | — | |
P/B ratio |
5.82 | 2.97 | — | — | |
Price to Tangible BV |
5.82 | 2.97 | — | — | |
EV/Sales |
11.71 | 10.99 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(5.34) | (4.94) | — | — | |
EV/FCF |
(5.31) | (4.90) | — | — | |
Quick Ratio |
8.31 | 15.85 | 26.51 | 49.95 | |
Current Ratio |
8.88 | 16.32 | 27.38 | 50.82 | |
Net Debt/EBITDA |
(10.89) | 8.15 | 7.68 | 16.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.24 | 0.17 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.95) | 0.77 | 0.97 | 0.70 | |
Capex/Depreciation |
30.20 | 0.77 | 0.00 | (0.04) | |
Research and Development Expense of Revenue |
57.27% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.58% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.31% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.12 | 0.29 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(10.95%) | (9.71%) | — | — | |
Free Cash Flow Yield |
(15.75%) | (13.60%) | — | — | |
Revenue per Share |
0.48 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (0.26) | (0.31) | (0.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.26) | (0.31) | (0.26) | |
Cash per Share |
1.38 | 2.96 | 2.65 | 6.77 | |
Shareholders Equity per Share |
1.44 | 2.98 | 2.73 | 6.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.44 | 2.98 | 2.73 | 6.84 | |
Free Cash Flow |
(31.10) | (29.94) | (44.36) | (38.85) | |
Working Capital |
145.34 | 332.08 | 378.00 | 1,011.37 | |
Capital Expenditures |
(0.15) | (0.22) | 0.00 | 0.02 | |
Net Current Asset Value |
113.67 | 301.25 | 348.04 | 982.32 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
3.17 | 1.39 | 2.83 | 2.21 | |
Average Assets |
281.28 | 357.59 | 355.05 | 655.89 | |
Average Common Equity |
194.60 | 272.85 | 279.13 | 579.74 |
Columns are period end dates